Medicare Enrolled
Dr. Ram Vasudevan, M. D.
Cardiovascular Disease · Ocala, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Vasudevan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vasudevan? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vasudevan
Dr. Ram Vasudevan is a cardiovascular disease in Ocala, FL, with 20 years in practice. Based on federal Medicare data, Dr. Vasudevan performed 21,818 Medicare services across 9,963 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vasudevan received a total of $3,264 from 16 pharmaceutical and/or device companies across 45 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vasudevan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 1% volume in FL$ $3,264 industry payments
Medicare Practice Summary
Medicare Utilization ↗21,818
Medicare services
Top 1% in FL for cardiovascular disease
9,963
Unique beneficiaries
$72
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,091 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 3,357 | $0 | $5 |
| Chronic care management, additional 20 min/month | 1,648 | $37 | $90 |
| Office visit, established patient (30-39 min) | 1,647 | $90 | $215 |
| Chronic care management, first 20 min/month | 1,441 | $48 | $75 |
| Regadenoson injection (Lexiscan) for heart stress test | 768 | $44 | $115 |
| Hospital follow-up visit, moderate complexity | 648 | $62 | $147 |
| Cortisol (hormone) measurement, total | 519 | $16 | $40 |
| Lipoprotein (a) level | 518 | $14 | $20 |
| Homocysteine (amino acid) level | 504 | $18 | $30 |
| Electrocardiogram (EKG), 12-lead | 495 | $10 | $34 |
| Natriuretic peptide (heart and blood vessel protein) level | 455 | $38 | $60 |
| Chronic care management services for two or more chronic conditions, additional 30 minutes provided personally by health care professional, per calendar month | 407 | $47 | $85 |
| Magnesium level test | 405 | $7 | $16 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 384 | $313 | $1,150 |
| Blood draw (venipuncture) | 330 | $8 | $10 |
| Echocardiogram, transthoracic | 322 | $141 | $449 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 298 | $20 | $75 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 297 | $50 | $152 |
| Troponin (protein) analysis, quantitative | 290 | $12 | $24 |
| Apolipoprotein level | 284 | $21 | $30 |
| Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | 276 | $66 | $120 |
| Remote patient monitoring device, 30 days | 270 | $35 | $128 |
| Remote patient monitoring management, 20 min/month | 270 | $35 | $128 |
| Ultrasound of both sides of head and neck blood flow | 256 | $141 | $398 |
| Hospital follow-up visit, high complexity | 253 | $91 | $214 |
| Ultrasound of leg arteries or artery grafts | 245 | $180 | $508 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 244 | $18 | $85 |
| Measurement c-reactive protein for detection of infection or inflammation, high sensitivity | 243 | $13 | $25 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 241 | $28 | $150 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 229 | $50 | $180 |
| Remote pacemaker monitoring, 90 days | 223 | $22 | $90 |
| Complete ultrasound study of arm and leg arteries | 220 | $94 | $350 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 192 | $2,062 | $2,700 |
| External counterpulsation, per treatment session | 190 | $77 | $270 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 184 | $88 | $600 |
| Remote pacemaker/defibrillator monitoring, 90 days | 183 | $17 | $51 |
| Initial hospital admission, high complexity | 181 | $137 | $413 |
| Programming of dual lead pacemaker system | 175 | $57 | $117 |
| Injection of drug or substance into vein | 147 | $28 | $80 |
| Creatine kinase (cardiac enzyme) level, total | 112 | $6 | $18 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 112 | $27 | $138 |
| Prothrombin time test (blood clotting) | 105 | $4 | $11 |
| Ultrasound of aorta, vena cava, groin vessels or bypass grafts | 103 | $85 | $200 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 100 | $137 | $387 |
| Uric acid level test | 97 | $4 | $11 |
| Evaluation of implantable heart and blood vessel monitoring system | 97 | $40 | $85 |
| Thyroid hormone, t3 measurement, free | 95 | $17 | $25 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 92 | $329 | $954 |
| Folic acid level test | 89 | $14 | $40 |
| Lactate dehydrogenase (enzyme) level | 86 | $6 | $16 |
| Urine microalbumin (protein) analysis | 84 | $6 | $12 |
| Free thyroxine (T4) test | 84 | $9 | $25 |
| Testing of autonomic nervous system function and heart rate response to deep breathing | 83 | $66 | $136 |
| Testing of autonomic (sympathetic) nervous system function | 83 | $94 | $209 |
| Vitamin B-12 level test | 82 | $15 | $41 |
| Programming of multiple lead implantable defibrillator system | 81 | $79 | $179 |
| Thyroid stimulating hormone (TSH) test | 79 | $16 | $46 |
| Creatinine test (kidney function) | 75 | $5 | $13 |
| New patient office visit, complex (60-74 min) | 68 | $152 | $419 |
| Transitional care management services for problem of high complexity | 65 | $215 | $462 |
| Automated urinalysis | 60 | $2 | $4 |
| Lipid panel (cholesterol and triglycerides) | 56 | $13 | $33 |
| C-reactive protein test (inflammation marker) | 45 | $5 | $8 |
| Evaluation of cardiac rhythm monitor system | 45 | $35 | $74 |
| Complete blood count (CBC) with differential | 44 | $8 | $21 |
| Transitional care management services for problem of at least moderate complexity | 43 | $147 | $327 |
| Comprehensive metabolic blood panel | 37 | $10 | $35 |
| Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | 37 | $33 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 34 | $16 | $79 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 34 | $11 | $34 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 34 | $89 | $236 |
| Initial hospital admission, moderate complexity | 32 | $103 | $284 |
| Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | 28 | $990 | $2,200 |
| Programming of dual lead implantable defibrillator system | 28 | $74 | $164 |
| Insertion of heart rhythm monitor under skin | 26 | $3,244 | $6,500 |
| New patient office visit (45-59 min) | 22 | $110 | $331 |
| Destruction of first incompetent vein of arm or leg using radiofrequency and imaging guidance | 20 | $831 | $3,002 |
| Ultrasound of heart, follow-up | 17 | $75 | $245 |
| Insertion of implantable defibrillator system | 15 | $739 | $1,967 |
| Interpretation and report of ultrasound of heart | 15 | $71 | $189 |
| Office visit, established patient, complex (40-54 min) | 12 | $140 | $365 |
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 12 | $66 | $208 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $422 | $1,120 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
5.7% high complexity
26.8% medium
67.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,264
Total received (2018-2024)
Avg $466/year across 7 years
Top 50% in FL for cardiovascular disease
16
Companies
45
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,264 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,522
2023$186
2022$51
2021$96
2020$127
2019$189
2018$1,092
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Abbott Laboratories
$1,640
BIOTRONIK INC.
$969
Medtronic Vascular, Inc.
$159
Boston Scientific Corporation
$114
Novartis Pharmaceuticals Corporation
$102
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$49
Genentech USA, Inc.
$44
Foundation Medicine, Inc.
$42
CVRx, Inc.
$25
PFIZER INC.
$24
Gilead Sciences, Inc.
$20
BOSTON SCIENTIFIC CORPORATION
$19
Merck Sharp & Dohme Corporation
$18
AstraZeneca Pharmaceuticals LP
$13
Janssen Pharmaceuticals, Inc
$13
Medtronic, Inc.
$12
Top 3 companies account for 84.8% of total payments
Associated products mentioned in payments ›
ASSURITY · AVEIR · BRILINTA · Barostim Neo System · Claria MRI · ELIQUIS · ENTRESTO · FOUNDATIONONE · GAZYVA · JOT DX · LUX-DX · LifeVest · Phesgo · Reveal LINQ · SQ-RX PULSE GENERATOR · Trodelvy · VERQUVO · VenaSeal · WATCHMAN · XARELTO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $15 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
43
Per 100K population
11.1
County median income
$58,535
Nearest hospital
ADVENTHEALTH OCALA
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Vasudevan is a clinical cardiology specialist, with above-average Medicare volume (top 1% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Vasudevan experienced with injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)?
Based on Medicare claims data, Dr. Vasudevan performed 3,357 injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vasudevan receive payments from pharmaceutical companies?
Yes. Dr. Vasudevan received a total of $3,264 from 16 companies across 45 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vasudevan's costs compare to other cardiovascular diseases in Ocala?
Dr. Vasudevan's average Medicare payment per service is $72. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vasudevan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Ocala
Browse cardiovascular diseases in Ocala ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in FL
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in FL
Which FL cardiovascular diseases receive the most from drug and device companies.
By company
Abbott Laboratories Payments to Doctors
See all physicians who received payments from Abbott Laboratories.
By company
BIOTRONIK INC. Payments to Doctors
See all physicians who received payments from BIOTRONIK INC..
By company
Medtronic Vascular, Inc. Payments to Doctors
See all physicians who received payments from Medtronic Vascular, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology